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Description
This study was designed to evaluate the mydriatic effects of patients being dilated under differing illumination
conditions. Twenty subjects, 1 a females and 1 a males, had their pupils dilated under darkened conditions
and under normal illumination to determine if there would be a difference in the rate of mydriasis or overall
pupil size at the point of maximum dilation. Iris colour and gender were separately evaluated factors in
dilation results. Subjects were dilated using one drop each of 1% tetracaine, 2.5% phenylephrine HCI and 1%
tropicamide. Pupil diameter was periodically measured using a Cogan pupillometer starting 6 minutes after
drop instillation. Measurements with the pupillometer were taken at two-minute intervals throughout the 3 a-
minute test period. The final measurement 33 minutes after instillation of the dilating drops was taken with a
biomicroscope reticule; both horizontal and vertical diameters were measured. No Significant differences
were seen between gender, iris colour and illumination type on the rate of maximum mydriasis. However, the
relative pupil area was significantly greater following dilation under normal illumination conditions.
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The effect of illumination on the time to, and pupil area of, 
maximum mydriasis 
Rachel L Rushforth, Rodney L White, Kathleen R Solum, Hannu RV Laukkanen 
Abstract: This study was designed to evalua'te the mydriatic 
ejjects of patients being dilated under differing illumination 
conditions. Twenty subjects, 1 a females and 1 a males, had 
their pUpils dilated under darkened conditions and under 
normal illumination to determine if there would be a 
difference in the rate of mydriasis or overall pUPil size at the 
point of maximum dilation. Iris colour and gender were 
separately evaluated factors in dilation results. Subjects were 
dilated using one drop each of 1 % tetracaine, 
2.5% phenylephrine HCI and 1% tropicamide. PUPil diameter 
was periodically measured using a Cogan pupillometer 
starting 6 minutes after drop instillation. Measurements with 
the pupillometer were taken at two-minute intervals 
throughout the 3 a-minute test period. The final measurement 
33 minutes after instillation of the dilating drops was taken 
with a biomicroscope reticule; both horizontal and vertical 
diameters were measured. No Significant differences were seen 
between gender, iris colour and illumination type on the rate 
of maximum mydriasis. However, the relative pUPil area was 
significantly greater following dilation under normal 
illumination conditions. 
Resume,' Cette etude avait pour but d'evaluer les ejjets 
mydriatiques de differentes conditions d'eclairement de l'oeil. 
Vingt sujets, c'est-a-dire dix femmes et dix hommes, ont ete 
soumis a des conditions d'assombrissement et d'eclairement 
normal afin de determiner si le taux de dilatation pupillaire 
ou la taille globale des pupilles serait differente a leur dilata-
tion maximale. On a evalue separement la couleur de !'iris et 
le sexe des sujets dans les resultats. On a instille aux sUjets une 
goutte chacun de tetracaine 1 %, de phenylephrine HCl2,5 % 
et de tropicamide 1 % et mesure a intervalles periodiques le 
diametre des pupilles a l'aide d'un pupillometre de Cogan, 
6 minutes apres !'instillation. Les releves au pupillometre ont 
eu lieu to utes les deux minutes pendant la perioded'essai de 
30 minutes. La derniere mesure, survenue 33 minutes apres 
!'instillation des gouttes mydriatiques, a ete faite a l'aide d'un 
biomicroscope a reticule, permettant ainsi de mesurer les 
diametres horizontal et vertical. On n'a degage aucun ecart 
pertinent du taux de dilatation pupillaire maximale selon le 
sexe, la couleur de l'iris ou Ie type d'eclairement. Toutefois, la 
superficie de la pupilte eta it beaucoup plus grande apres 
dilatation que sous un eclairage normal. 
Y OU have just finished placing mydriatiC agents in the eyes of your patient: Do you now seat them in a dark or a well-lit room? Several studies have 
explored how drop size, patient age or iris colour affects 
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dilation rate and final pupil size. However, few studies 
have considered the effect of room illumination upon 
pharmaceutical-induced mydriasis. 
Despite patient inconvenience and increased examina-
tion time, .dilated fundus exams are becoming more 
routine in today's optometric practice. To reach an 
acceptable mydriatic state of optimal retinal viewing 
requires a 20- to 30-minute wait after the instillation of the 
mydriatic drops; yet, the procedure for a thorough evalua-
tion of the retina may only require a few minutes. In 
today's fast-paced world, time spent waiting for the 
patient to dilate is a valuable commodity to both the 
patient and the optometrist. Therefore, any factor that 
could provide a faster or more complete mydriasis should 
be investigated, especially an option as simple as placing 
the patient in either a light or a dark environment while 
the drug takes effect. 
Several pharmaceuticals, in varying concentrations, are 
available for use in dilating patients. The clinical drug 
combination of choice continues to be 2.5% phenyle-
phrine HCI and 1 %. tropicamide. 1 For this reason, we 
chose to use this drug combination to evaluate the effect 
of illumination on the dilation process. 
Drug characteristics of phenylephrine Hel 
Phenylephrine is a direct-acting alpha-adrenergic agent 
that provides mydriasis without cy.cloplegic effects. It 
may also be used as an ocular decongestant or to break 
or prevent posterior synechia in uveitis. 2 Phenylephrine 
2.5% is the recommended concentration for routine 
fundus examinations. At this concentration, maximum 
mydriasis should occur 15 to 60 minutes post-drop. 
Recovery to pre-drop pupil size .will most likely occur in 
3 hours.3 
. Clinically, topical use of 2.5% phenylephrine in 
conju~ction with punctal occlusion induces few serious 
side effects, but there may be mild ocular reactions. These 
mild ocular reactions include transient stinging on instilla-
tion, irritation, headache, brow :;l.che, blurred vision, 
transient epithelial keratitis, allergic reactions and reactive 
hyperemia.3 Repeated doses of phenylephrine may cause 
rebound miosis or reduce the mydriatic effect needed for 
ophthalmic surgery. Therefore, excessive or repeated use 
with elderly patients should be avoided. 3 
CANADIAN JOURNAL OF OPTOMETRY 
Systemic complications are primarily cardiovascular in 
nature and include palpitations, tachycardia, arrhythmia, 
hypertension, reflex bradycardia, coronary occlusion, 
pulmonary embolism, subarachnoid haemorrhage, 
myocardial infarction, stroke and even death. 3 
Caution is recommended when using phenylephrine 
with patients who have cardiac disease, hypertension, 
atherosclerosis or diabetes or who are pregnant. It should 
not be used if a patient is hypersensitive to any 
component of the formulation or has indication of 
possible angle closure. In addition, drugs that interact 
with phenylephrine, such as tricyciic antidepressants, 
MAO inhibitors, reserpine, guanethidine and methyldopa, 
are contraindicated. 3 
Drug characteristics of tropicamide 
Tropicamide is an anticholinergic agent that is primarily 
used to dilate the pupil for fundus examinations and to 
prevent posterior synechiae dllring uveitis or trauma. The 
cycloplegic effect of tropicamide is also benefiCial in 
determining refractive errors when a relaxed accommoda-
tive system is needed.2 Although it is classified as a cyclo-
plegic agent, tropicamide is considered the drug of choice 
for mydriasis due to its quick onset and short duration of 
action. 3,4 As a mydriatic agent, tropic amide provides 
maximum dilation 20 to 40 minutes post-drop. The pupil 
usually recovers to the pre-dilation state within 6 hours 
of instillation.3 
When tropiearnide is used in conjunction with punctal 
occlusion, systemic side effects are lessened. However, the 
patient should be educated about the potential for ocular 
and systemic effects. Ocular reactions may include 
increased punctate keratitis and possible allergic reactions. 3 
Systemic side effects include CNS disturbances, flushing and 
dryness of the mouth and skin, headache, a rapid irregular 
pulse, irritability, bladder distention, hallucinations, drowsi-
ness, decreased gastrointestinal motility, coma, medullary 
paralysis and, in very rare instances, death. 3 
Cycloplegic mydriatics should not be used with patients 
who are pregnant or hypersensitive to the formulation, or 
who have posterior synechiae, primary open-angle 
glaucoma or a potential for angle-closure glaucoma. 3 
Pharmacological mechanism of mydriasis 
There are two separately innervated muscles involved in 
pupil mydriasis: the iris sphincter and the iris dilator. 
Tropicamide blocks cholinergic stimulation to the 
sphincter muscle of the iris and the ciliary body causing 
both pupil dilation and accommodative paralysis .. In 
contrast, phenylephrine acts as an alpha receptor agonist, 
causing contraction of the iris dilator muscle acting on the 
radial fibres. Other nonmydriatic effects that occur simul-
taneously with the use of phenylephrine include constric-
tion of the arteriole smooth muscle (causing "blanching" 
- of the conjunctiva) and the widening of the palpebral 
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fissure by stimulation of Mueller's muscle. The combined 
use of both a parasympatholytic (tropicamide) and a 
sympathomimetic (phenylephrine) provides maximal 
dilation that is resistant to intense light stimulation. 5 
Physiological and anatomical influences on 
drug absorption 
One of the most important aspects of pharmacokinetics is 
the absorption phase. Without adequate absorption, drug 
distribution and metabolism are altered and the intended 
effect does not occur. Absorption depends on the 
molecular properties of the drug, the penetrating factor 
of the tissue, the patient's age, iris pigmentation and 
tear flow. 6 
The major topical drug-absorbing tissue of the eye is the 
avascular cornea. The corneal epithelium acts as a 
reservoir for lipophilic drugs, 'and the stroma stores 
hydrophilic drugs. Any disruption' of the corneal epithe-
lium can affect drug absorption. The use of topical 
,anaesthetiC, or any abrasion to the cornea, can cause an 
increase in corneal penetration of mydriatic drugs. 
Phenylephrine has characteristics that may lead 
to corneal epithelium disruption. 7 This change in 
corneal integrity may lead to an increase in both the effect 
and the duration of the phenylephrine- and tropicamide-
induced mydriasis.3,4,8 
Other ocular tissues and structures have limited effects 
on drug absorption. The sclera and conjunctiva account 
for less than one-fifth of all drug absorption into the iris 
and ciliary body because they are so highly vascular-
ized.9,lO Pigment granules within the iris absorb drugs 
with lipophilic properties and slowly release that drug 
over a period of time. 
Anecdotal clinical evidence has suggested that dark 
irides take longer to dilate than light-coloured irides, but 
this has not been supported by studies comparing the 
dilation rate in light versus dark irides using 0.5% tropi-
camide. 5,11 Furthermore, the ciliary body is involved with 
drug detoxification and elimination and is the major drug-
metabolizing tissue of the anterior segment. 
Tears play a major role in the process of drug absorp-
tion. Only 30 I-IL can be held by the palpebral conjunctiva 
and fornix at one time, which includes the 8 to 10 !-1L of 
normal tear volume. Therefore, too large a volume or too 
many drops will simply roll off the cheek or pass through 
the puncta, resulting in no increase in the desired pharma-
cological effects of thedrug.4,12 Similarly, ocular pharma-
ceutical agents may become diluted from reflex tearing if 
the drugs sting upon instillation, which would further 
increase tear volume. Increasing drop size has no effect in 
increasing drug absorption. . 
Increased absorption of a drug may occur with people 
who have a decreased tear flow rate such as elderly 
patients, patients with rheumatoid arthritis or keratocon-
junctivitis sicca, or postmenopausal women.4 
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Concerns about dilation 
When compared to an undilated pupil, a dilated pupil 
facilitates locating and identifying posterior segment 
anomalies and ab.normalities by providing an. increased 
viewing area. However, there are drawbacks with pupil 
dilation. Increased examination time, patient inconve-
nience and the fear 'of systemic and ocular side effects are 
commonly cited reasons why some practitioners do not 
routinely dilate and why some patients refuse dilation.4 
Most patient objections can be overcome with proper 
education. Most patients want the assurance that their 
optometrist is providing them with the best possible care. 
Benefits of dilation include an increased viewing area for 
accurate peripheral fundus assessment and clear stereo 
views to assist diagnosis. By simply explaining the benefits 
of dilation, the optometrist can make the patient feel more 
comfortable and assured that they are getting proper care. 
Also, patient comfort after the dilation can be enhanced 
by reducing the photophobic effects through use of 
mydriatic glasses or Rev-Eyes, a drug that reverses 
mydriasis by blocking the alpha-adrenergic receptors in 
the iris dilator. 13 Patient risk associated with potential side 
effects can be minimized if the administrating doctor is 
pharmacologically current, well educated and prudent. 
Most topically applied pharmaceuticals used for pupil 
dilations are relatively safe. Mydriatics and cycloplegics, 
according to Rengstorff and Doughty, "have a history of 
extensive use in ophthalmic practice and ... serious 
complications are rare. When they do occur, they are 
often related to dosage, use with other drugs, surgery, 
trauma and very ill patients.,,2 Bartlett and Jaanus also 
suggest that the avascularity of the cornea provides a 
direct route for drug penetration without absorption by 
systemic Circulation, thus minimizing systemic side 
effects.4 Applebaum and Jaanus presented a study demon-
strating the safety of diagnostic pharmaceutical applica-
tion (DPA) by using data collected by the Southern 
California College of Optometry and 20 other private 
practices. 14 Of the 12,493 DPA cases, only 6 patients 
showed minor side effects with the use of tropicamide or 
phenylephrine. The best way to prevent harmful side 
effects is to avoid circumstances where known character-
istics and conditions are expected to trigger unwanted 
reactions. The optometrist should know the properties, 
recommended uses, and precautions and contraindica-
tions of every drug he or she administers. 
Project goals 
The intent of this study was to investigate whether the 
time needed for maximum mydriasis could be decreased or 
whether the amount of mydriasis could be increased by 
altering room illumination during dilation. Based on our 
understanding of the pharmaceutical properties of tropi-
camide and phenylephrine, and the physiology involved in 
pupil mydriaSiS, we predict that pupil dilation will occur 
faster if patients are placed in a darkened room rather than 
a well-lit room following instillation of the topical dilation 
drops. In a dark room, the iris sphincter will relax with 
natural pupil dilation, and the parasympatholytic drug will 
not be opposed by light-induced antagonistic muscle 
constriction. Likewise, the sympathomimetic drug will be 
acting as an agonist in the natural direction with pupil 
dilation during darkness. Therefore, pharmaceutical 
dilation in darkness should put the system in harmony to 
achieve faster and more complete mydriasis. 
Subjects and methods 
Subjects 
Twenty subjects-l0 females and 10 males between the 
ages of 19 and 37 years-participated in this study. All 
subjects reported themselves to be in good health and free 
of significant systemiC, neurologic and ocular diseases. 
Only subjects who had not experienced allergies or 
adverse reactions to anaesthetics or" dilating agents in the 
past were included in this study. All participants had 
vision correctable to 20/20, unremarkable slit lamp 
findings and anterior chamber angles greater than 3 via 
Van Herick technique. Before participation in the study, 
informed consent was obtained from each subject. 
Methods 
The initial examination of the subjects included a 
thorough biomicroscopy evaluation to assess the general 
ocular health of each eye and Goldmann tonometry to 
measure intraocular pressures. One dfop of 1 % tetracaine 
was instilled into each lower fornix just before performing 
tonometry. Care ·was taken to minimize any systemic 
absorption by occluding the puncta and having subjects 
close their eyes for 15 seconds. Anterior chamber angles 
were determined by using Van Herick and shadow 
methods. In addition, eye colour was classified as either 
light or dark. 
Subjects were then randomly placed in either a dark or 
a well-illuminated room. By using a photometer in the illu-
minated rooms, light levels were controlled at 22 foot-
candles. A baseline horizontal pupil diameter was 
measured using the Cogan pupillometer. 
The Cogan pupillometer is a hand-held card that has a 
series of paired pinholes. The horizontal separation 
between the paired pinholes increases by 0.5 mm with 
each pair down the card. The vertical spacing is uniform 
between the paired pinholes. When the card is held at a 
. common vertex distance from the eye, the subject can see 
through a pair of two tiny holes simultaneously. While 
viewing a distant light target, the subject subjectively 
moves the card up and down until the two holes appear 
to just touch without overlap or separation. From this 
"ideal" pinhole separation distance, a pupil diameter can 
be determined. 15 When the procedure was performed in a 
light room, subjects viewed a white wall at 6 metres 
under ambient room illumination as previously described; 
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when the procedure was performed in a dark room, 
subjects viewed a UV "black light" positioned 6 metres in 
front of them. 
After each subject was trained in the proper use of the 
Cogan pupillometer, a baseline pupil diameter measure-
ment was obtained for each eye in normal room illumina-
tion. One drop of 2.5% phenylephrine HCI was then 
instilled into the lower fornix of each eye and the timer 
was started. After 15 seconds, one drop of 1 % tropicamide 
was instilled into each eye. Room lights were extin-
guished immediately during dark dilation. In each 
instance, precautions were taken to minimize systemic 
absorption through the use of punctal occlusion. Subjects 
were encouraged to keep their eyes open and to look into 
the distance for the duration of the experiment. Six 
minutes after instillation of the first drop, subjects were 
asked to measure their horizontal pupil diameter with the 
Cogan pupillometer. After the subjects identified the 
pinhole pair that yielded touch without overlap or separa-
tion, the examiner then noted the pupil size equivalent 
from the front of the card. Subjects were unaware of 
which pupil sizes corresponded to the pinhole pairs. 
Following this pupil size determination, measurements 
were taken every 2 minutes tmtil 30 minutes had elapsed. 
. At 30 minutes, normal room illumination (22 foot-candles) 
was resumed for those subjects who were dilated under 
dark illumination conditions. After a further 3 minutes in . 
the light (i.e., 33 minutes after the instillation of the 
drops), a final horizontal and vertical pupil diameter was 
measured using the slit lamp reticule. Tonometry was 
then repeated to check for any significant intraocular 
pressure (lOP) changes. The subjects then returned in one 
week to complete the protocol with the alternate illumi-
nation condition. A minimum of one week was required 
between dilations to prevent any possibility of an additive 
effect of the dilation pharmaceuticals. 
In the remainder of this paper, .subjects dilated in a _ 
well-lit room may be referred to as "light dilation" and 
those subjects dilated in a dark room may be referred to as 
"dark dilation". 
Statistical analysis 
The time to maximum mydriasis was arbitrarily classified 
as the time after which subjects chose the same pinhole 
pair for five consecutive readings, thus indicating a pupil 
size fluctuation of no. more than 0,5 mm. Readings were 
recorded for both eyes and then a mean time was deter-
mined for each subject. 
Paired t-tests were used to compare the time required in 
the dark to the time required in the light for maximum 
mydriasis to occur. Unpaired t-tests were used to analyse 
the effects of iris colour. The mean times to maximum 
dilation with dark irides were compared to those with 
light irides in the illuminated room. Then the same 
computations were made with the results obtained in the 
darkened room. Unpaired t-tests were used in a similar 
fashion to compare times to maximum dilation of males to 
females under the same illumination conditions. 
An average horizontal pupil measurement was calcu-
lated from both the eyes using the slit lamp reticule. 
Similarly, an average vertical pupil measurement was 
calculated. Paired t-tests were used to compare mean hori-
zontal and mean vertical pupil diameters in a light room. 
The same comparison was made for data obtained from 
the dark-room condition. The relative pupil area was 
determined by considering the pupil as an ellipse rather 
than a circle. Thus, a relative pupil area was calculated 
using the formula (nvh)/4, where "v" is the maximum 
vertical pupil diameter and "h" is the maximum horizontal 
pupil diameter. A paired t-test was then used to compare 
dark dilation versus light dilation relative to pupil area for 
each subject at 33 minutes post drug instillation. In 
addition, a paired t-test was used to compare mean hori-
zontal and mean vertical pupil measurements that were 
taken under the same lighting conditions. 
The gender versus pupil size comparison was made 
using an unpaired t-test to compare the mean relative 
pupil area for males versus females who were dilated 
under the same lighting conditions. Similarly, an unpaired 
t-test was used to determine if iris colour had any effect on 
the size of the dilated pupil area . 
Results 
Time to maximum. mydriasis 
Table 1 presents the mean time to maximum mydriasis, as 
measured by Cogan pupillometer, for the 20 subjects who 
experienced light dilation and dark dilation. Although the 
subjects dilated faster in a dark room with a mean time of 
18.1 minutes compared to the mean of 19.7 minutes for 
dilation in a well-lit room, the one-tailed paired t-test 
indicated that there was no significant difference (p > 
0.05) between light and dark colour irides. That is, in a 
light room there was no difference in the time required 
for subjects with dark irides to dilate compared to those 
subjects with light irides. Similarly, when the dilation 
process was completed in a dark room, there was no 
significant difference in the time to maximum dilation. 
Relative area of pupil dilation 
Table 2 presents the slit lamp pupil measurements 
obtained from the 20 subjects at 33 minutes post instilla-
. tion of the mydriatic drops. When comparing the relative 
pupil area of subjects dilated in dark conditions versus 
Table 1. Tilne to maximwn mydriasis (with standard 
deviations) 
mwnination Nwnberof Males/ Mean time to. 
level subjects Females mydriasis in 
minutes 
light 20 1/1 19.7 (4.3) 
dark 20 1(1 IS.1 (4.4) 
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-Table 2. Mean pupil measurements at 33 minutes after 
tropicamide 1% and phenylephrine Hel 2.5% were 
instilled (with standard deviations) 
Dlumination Mean horizontal Mean vertical Mean relative 
condition pupil diameter pupil diameter pupil area in 
inmm inmm mm2 
light 8.12 (0.65) 8.07 (0.64) 51.73 (7.60) 
dark 7.94 (0:55) 7.91 (0.62) 49.55 (7.01) 
mean difference 0.18 = 0.16mm 2.18=2 
light conditions using a paired t-test, there was a signifi-
cant difference (p < 0.05). Subjects diiated in a well-lit 
room had a significantly increased relative pupil area 
compared to dark dilation. 
When considering only the mean horizontal diameter of 
the pupil, dilation during light conditions yielded a signifi-
cantly (p < .0.05) larger horizontal diameter than dark 
dilation. However, the vertical pupil diameter differences 
fell just short of significance (p > 0.05). This surprising 
finding indicates that more of the increased relative area 
obtained from light dilation is derived from the horizontal 
measure. Within the same lighting conditions, there was 
not a significant difference between the horizontal and 
vertical pupil diameter measurements (p > 0.05). 
There was no significant pupil size relationship 
between males and females or between light and dark iris 
colours within the same set of illumination conditions 
using unpaired t-tests (p > 0.05). 
Subjective response 
During the dark dilation procedure, when the lights were 
turned on 30 minutes after drop instillation, many subjects 
complained of discomfort due to the bright lights. The 
same subjects in the light dilation procedure did not 
report this discomfort. 
Discussion 
The goals of this project were to determine whether the 
speed or size of maximum dilation would be different if 
the patient were dilated in a darkened room versus a well-
lit room. In other words, do illumination conditions after 
drop instillation affect pupil dilation? Also, we were inter-
ested whether gender differences or iris colour would 
influence dilation results. 
Contrary to our original prediction, this study showed 
that placing a patient in a dark room does not result in a 
significantly faster dilation than dilating the patient in a 
well-lit room. Although dilation rate indicated a trend 
toward a slightly faster dilation in the dark, it is conceiv-
able that our measurements were influenced by differ-
ences in chromatic aberration between light and dark 
conditions. Allowing the patient to dilate in a dark room 
did improve overall comfort. However, this initial comfort 
is short-lived because the patient will soon be subjected to 
the bright lights of an indirect ophthalmoscope. Perhaps 
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waiting for this procedure in a well-lit room will lessen the 
discomfort of the bright lights to come. 
Based on slit lamp measurements 33 minutes after 
dilation, there was a significant difference (p < 0.05) in 
the relative pupil area when patients dilated in a dark 
room compared to a light room. Unexpectedly, the 
relative pupil area obtained from light dilation produced a 
greater mean pupil area by 2.18 mm2 than that from dark 
dilation. Although we do not know exactly why, one 
possible explanation may be that in the light, the iris is 
constricted and thus more area of iris and ciliary body is 
exposed and available for absorption of mydriatic agents. 
SurpriSingly, it was the horizontal pupil diameter that was 
statistically larger, whereas the vertical pupil measure-
ment was not. This may be explained by the natural 
pooling of the mydriatic in the palpebral fissure in the 
horizontal meridian. With the eyes open, fluid will tend to 
accumulate in the horizontal meridian along the lower lid 
margin and the blinking action may push fluid toward the 
fissure. In a well-lit room, we believe that the lids may 
tend to assume a more squinted posture than in the dark, 
thus narrowing the palpebral fissure and decreasing the 
vertical width of the drug reservoir in contact with the 
front surface of the eye. Increased drug concentration 
along the fissure could conceivably increase the drug 
availability to the cornea and might explain the greater 
horizontal mydriasis obtained from a light dilation. We call 
this our "serendipitous sectoral mydriasis explanation". 
Neither gender nor iris colour was a factor in either the 
rate to maximum mydriasis or the difference of relative 
pupil area. Our finding that gender has no impact on 
dilation results was expected, since ·there are no anatom-
ical differences between healthy male and female eyes 
that would increase or decrease drug absorption. Our 
finding that iris colour has no significant effect is consis-
tent with past research, which has shown that iris colour 
(categorized as light or dark) has no significant effect' in 
the amount or rate of dilation.5,lI 
The ambient illumination during patient dilation is 
usually determined by the doctor,rather than the patient, 
For patient comfort one may recommend low illumination 
during dilation. However, our results demonstrate that 
dilation with low light levels is not. Significantly faster and 
may yield a pupil area that is slightly smaller, although this 
difference is probably not clinically Significant, The bottom 
line is that although patient comfort may be slightly 
enhanced with dark dilation, the patient is not going to be 
ready for the fundus examination any faster, One might 
argue that is preferable to have the patient sit in the 
reception area and enjoy the company of friends or other 
patients. The additional benefits of undergoing dilation in a 
well-lit room include not only the increased final dilation 
area, but also, as the dilation progresses, the gradual adap-
tation of the eyes to the increased light reaching the retina, 
After all, it seems paradoxical during the dilation to place 
the patients in a dark room for comfort when, moments 
later, very bright lights will be aimed directly through their 
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fully dilated pupils. In the future, after instillation of the 
mydriatic drops, we will seat our patients in a well-lit room 
while the drops take effect. 
We would like to thank all those individuals who took part in 
our thesis and volunteered to be dilated. We express much 
appreciation to Dr Robert Yolton for all his help with the statis-
tics and valuable advice. In addition, we thank Dr Bradley Coffey 
for his help in obtaining information on the Cogan pupillometer. 
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